Quantum Tubers Corporation, quantum tubers, plant tissue culture, 
minitubers, mini-tubers, potato, potatoes, seed potato, seed potatoes, 
agricultural, agriculture, biotechnology, biotech, BioChamber, growth
 chamber, rapid growth, virus-free, pathogen-free, agtec, ag-tec, 
american, American Ag-Tec International, technology, agbiotech, 
biomanufacturing, worldwide, international, NASA.

Pharmaceuticals Applicaton

Pharmaceutical Use of Quantum Tubers Technology

"Who's Who in Plant-Made Pharmaceuticals"
IALS International Academy of Life Sciences: "Quantum Tubers - Company produced the world’s first full crop of pharmaceutical potatoes containing Hepatitis B Vaccine for Clinical tests using its proprietary biomanufacturing technology for mass multiplication of early generation nuclear seed materials for potato. Company’s cooperation with NASA has produced the world’s only system that will multiply clonal materials in isolation beginning with tissue culture through to physiologically mature minitubers in such a way that millions of zero generation clones are available for field or greenhouse production in the shortest time possible."[To see the complete article, click link above, scroll down to Quantum Tubers.]

"Companies to Watch For"
Larta Institute - [2008-2009 NIH Commercialization Assistance Program participant.] "Quantum Tubers Corporation specializes in the controlled-environment growth of plants. The company has experience with many genetically engineered plants and has developed the first cGMP protocols for use with pharmaceuticals produced with plants. Through their work with Roswell Park Cancer Institute, Cornell University's Boyce Thompson Institute for Plant Research, and Arizona State University's Biodesign Institute, via their previous work in vaccine-gearing plants, Quantum Tubers is producing potatoes bearing HBsAg surface antigen for hepatitis B vaccine production. This product has already been tested using healthy humans in a double-blind, clinical trial with measured results. A company has been formed around this vaccine product and a Phase II SBIR will allow them to produce a shelf-stable, oral dose version of this vaccine through the first stage of FDA authorization of this new vaccine."

Home
Home
Overview
Overview
Technology
Technology
FAQ
FAQ
Data
Data
Photos
Photos
News
News

Quantum Tubers Corporation
P.O. Box 569, Delavan, WI 53115-0569 USA
Phone: 262-728-8815 ~ Fax: 262-728-8131
E-Mail: info@quantumtubers.com
Copyright © 1999 - 2007